Cargando…

The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells

Germline mutations in the tumor suppressor gene PTEN cause PTEN Hamartoma Tumor Syndrome (PHTS). Pediatric patients with PHTS frequently develop lipomas. Treatment attempts with the mTORC1 inhibitor rapamycin were unable to reverse lipoma growth. Recently, lipomas associated with PIK3CA-related over...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirstein, Anna S., Augustin, Adrien, Penke, Melanie, Cea, Michele, Körner, Antje, Kiess, Wieland, Garten, Antje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826943/
https://www.ncbi.nlm.nih.gov/pubmed/31627436
http://dx.doi.org/10.3390/cancers11101586
_version_ 1783465211826536448
author Kirstein, Anna S.
Augustin, Adrien
Penke, Melanie
Cea, Michele
Körner, Antje
Kiess, Wieland
Garten, Antje
author_facet Kirstein, Anna S.
Augustin, Adrien
Penke, Melanie
Cea, Michele
Körner, Antje
Kiess, Wieland
Garten, Antje
author_sort Kirstein, Anna S.
collection PubMed
description Germline mutations in the tumor suppressor gene PTEN cause PTEN Hamartoma Tumor Syndrome (PHTS). Pediatric patients with PHTS frequently develop lipomas. Treatment attempts with the mTORC1 inhibitor rapamycin were unable to reverse lipoma growth. Recently, lipomas associated with PIK3CA-related overgrowth syndrome were successfully treated with the novel PI3K inhibitor alpelisib. Here, we tested whether alpelisib has growth-restrictive effects and induces cell death in lipoma cells. We used PTEN-haploinsufficient lipoma cells from three patients and treated them with alpelisib alone or in combination with rapamycin. We tested the effect of alpelisib on viability, proliferation, cell death, induction of senescence, adipocyte differentiation, and signaling at 1–100 µM alpelisib. Alpelisib alone or in combination with rapamycin reduced proliferation in a concentration- and time-dependent manner. No cell death but an induction of senescence was detected after alpelisib incubation for 72 h. Alpelisib treatment led to a reduced phosphorylation of AKT, mTOR, and ribosomal protein S6. Rapamycin treatment alone led to increased AKT phosphorylation. This effect could be reversed by combining rapamycin with alpelisib. Alpelisib reduced the size of lipoma spheroids by attenuating adipocyte differentiation. Since alpelisib was well tolerated in first clinical trials, this drug alone or in combination with rapamycin is a potential new treatment option for PHTS-related adipose tissue overgrowth.
format Online
Article
Text
id pubmed-6826943
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68269432019-11-18 The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells Kirstein, Anna S. Augustin, Adrien Penke, Melanie Cea, Michele Körner, Antje Kiess, Wieland Garten, Antje Cancers (Basel) Article Germline mutations in the tumor suppressor gene PTEN cause PTEN Hamartoma Tumor Syndrome (PHTS). Pediatric patients with PHTS frequently develop lipomas. Treatment attempts with the mTORC1 inhibitor rapamycin were unable to reverse lipoma growth. Recently, lipomas associated with PIK3CA-related overgrowth syndrome were successfully treated with the novel PI3K inhibitor alpelisib. Here, we tested whether alpelisib has growth-restrictive effects and induces cell death in lipoma cells. We used PTEN-haploinsufficient lipoma cells from three patients and treated them with alpelisib alone or in combination with rapamycin. We tested the effect of alpelisib on viability, proliferation, cell death, induction of senescence, adipocyte differentiation, and signaling at 1–100 µM alpelisib. Alpelisib alone or in combination with rapamycin reduced proliferation in a concentration- and time-dependent manner. No cell death but an induction of senescence was detected after alpelisib incubation for 72 h. Alpelisib treatment led to a reduced phosphorylation of AKT, mTOR, and ribosomal protein S6. Rapamycin treatment alone led to increased AKT phosphorylation. This effect could be reversed by combining rapamycin with alpelisib. Alpelisib reduced the size of lipoma spheroids by attenuating adipocyte differentiation. Since alpelisib was well tolerated in first clinical trials, this drug alone or in combination with rapamycin is a potential new treatment option for PHTS-related adipose tissue overgrowth. MDPI 2019-10-17 /pmc/articles/PMC6826943/ /pubmed/31627436 http://dx.doi.org/10.3390/cancers11101586 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kirstein, Anna S.
Augustin, Adrien
Penke, Melanie
Cea, Michele
Körner, Antje
Kiess, Wieland
Garten, Antje
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title_full The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title_fullStr The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title_full_unstemmed The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title_short The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells
title_sort novel phosphatidylinositol-3-kinase (pi3k) inhibitor alpelisib effectively inhibits growth of pten-haploinsufficient lipoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826943/
https://www.ncbi.nlm.nih.gov/pubmed/31627436
http://dx.doi.org/10.3390/cancers11101586
work_keys_str_mv AT kirsteinannas thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT augustinadrien thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT penkemelanie thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT ceamichele thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT kornerantje thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT kiesswieland thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT gartenantje thenovelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT kirsteinannas novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT augustinadrien novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT penkemelanie novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT ceamichele novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT kornerantje novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT kiesswieland novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells
AT gartenantje novelphosphatidylinositol3kinasepi3kinhibitoralpelisibeffectivelyinhibitsgrowthofptenhaploinsufficientlipomacells